Core Insights - Zoetis, Inc. (ZTS) reported second-quarter 2025 adjusted earnings of $1.76 per share, exceeding the Zacks Consensus Estimate of $1.62 and up from $1.56 in the same quarter last year [1] - Total revenues for the quarter reached $2.46 billion, a 4% year-over-year increase, surpassing the Zacks Consensus Estimate of $2.40 billion and the previous year's revenue of $2.36 billion [1] Revenue Breakdown - The U.S. segment revenues increased by 4% year over year to $1.36 billion, beating both the Zacks Consensus Estimate of $1.33 billion and the model estimate of $1.31 billion [2] - Sales of companion animal products in the U.S. rose by 9% to $1.18 billion, driven by products like Simparica Trio and key dermatology items, although this was partially offset by a decline in monoclonal antibody sales for osteoarthritis pain [3] - International segment revenues grew by 3% year over year to $1.07 billion, exceeding the Zacks Consensus Estimate of $1.05 billion [7] - Ex-U.S. sales of companion animal products increased by 8% to $612 million, supported by growth in various key products [8] - Livestock product sales in the U.S. decreased by 21% to $180 million, primarily due to the divestiture of the medicated feed additive product portfolio [5] Future Guidance - Zoetis raised its 2025 adjusted earnings outlook to a range of $6.30-$6.40 per share, up from the previous range of $6.20-$6.30 [10] - Revenue guidance for 2025 was also increased to $9.45-$9.6 billion from the earlier range of $9.425 billion to $9.575 billion [10]

Core Insights - Zoetis reported revenue of $2.46 billion for the quarter ended June 2025, marking a year-over-year increase of 4.2% and an EPS of $1.76, up from $1.56 a year ago, exceeding both revenue and EPS estimates [1] Financial Performance - The reported revenue of $2.46 billion surpassed the Zacks Consensus Estimate of $2.4 billion by 2.44% [1] - The EPS surprise was +8.64%, with the consensus EPS estimate being $1.62 [1] Geographic Revenue Breakdown - U.S. Revenue: $1.36 billion, exceeding the average estimate of $1.33 billion, reflecting a year-over-year increase of 3.7% [4] - International Revenue: $1.07 billion, slightly above the estimated $1.05 billion, with a year-over-year change of +3.4% [4] - Companion Animal Revenue: $1.79 billion, surpassing the average estimate of $1.76 billion, showing an increase of 8.4% year-over-year [4] - Livestock Revenue: $638 million, slightly above the estimated $625.62 million, but down 8.1% compared to the previous year [4] Segment Performance - Contract Manufacturing & Human Health: Revenue of $34 million, significantly above the average estimate of $21.18 million, representing an 88.9% year-over-year increase [4] - Companion Animal - Horses: Revenue of $72 million, exceeding the estimate of $29.58 million, with a year-over-year increase of 5.9% [4] - Livestock - Poultry: Revenue of $103 million, below the average estimate of $115.27 million, reflecting a year-over-year decline of 22% [4] - Livestock - Cattle: Revenue of $320 million, above the estimate of $294.87 million, but down 8.6% year-over-year [4]

Financial Data and Key Metrics Changes - The company reported $2.5 billion in revenue, growing 4% on a reported basis and 8% on an organic operational basis, excluding foreign exchange and the MFA divestiture [21] - Adjusted net income of $783 million grew 10% on both a reported and organic operational basis [21] - Organic operational revenue growth was balanced, driven by 4% price and 4% volume [21] Business Line Data and Key Metrics Changes - The companion animal portfolio generated $1.8 billion in revenue, growing 8% operationally [22] - The Simparica franchise contributed $448 million, growing 17%, while the key dermatology franchise posted $460 million, growing 11% [22] - The livestock segment achieved 6% organic operational revenue growth, driven by strong international performance [18][22] Market Data and Key Metrics Changes - The U.S. market grew 4% on a reported basis and 7% on an organic operational basis, with companion animal growing 9% and livestock declining 2% [23] - International revenue grew 3% on a reported basis and 9% on an organic operational basis, with companion animal growing 8% and livestock growing 10% [28] Company Strategy and Development Direction - The company is raising its full-year guidance for organic operational revenue growth to 6.5% to 8% based on strong first-half performance [19] - The focus remains on executing with discipline, advancing meaningful innovation, and staying connected to customer needs [20] - The company aims to leverage its leadership position in the market and continue to drive growth through innovation and differentiated products [17][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the animal health sector, citing strong fundamentals and a diversified portfolio [20] - The company is focused on addressing competitive pressures and macroeconomic challenges while maintaining above-market growth [38] - Management highlighted the importance of compliance and education in driving adoption of new products like Librela [51][70] Other Important Information - The company is actively advancing its pipeline, with expectations for major market approvals every year for the next few years [71] - The adjusted gross margin was reported at 73.7%, with a favorable impact from foreign exchange [34] - The company continues to manage costs effectively while investing in long-term growth [61] Q&A Session Summary Question: Changes in strategy regarding competition in the Trioderm franchises - Management noted that they have not changed their strategy and continue to see strong growth in the Simparica franchise despite competition [45][46] Question: Expectations for Librela's growth and timing - Management is focused on medical education and third-party studies to support Librela's adoption, with expectations for growth potentially starting in 2026 [51][70] Question: Ability to achieve high single-digit operational growth next year - Management emphasized the broad-based results and innovation driving growth, with confidence in achieving above-market growth [58][60] Question: Strategies to promote Cytopoint in dermatology - Management highlighted the differentiated benefits of Cytopoint and the ongoing investment in all three dermatology products [78][79] Question: Clarification on contract manufacturing for human health - Management indicated that the increase in contract manufacturing is relatively small and not expected to be a recurring significant factor [83]

Financial Data and Key Metrics Changes - The company reported $2.5 billion in revenue for Q2 2025, growing 4% on a reported basis and 8% on an organic operational basis, excluding foreign exchange impacts and the MFA divestiture [19][20] - Adjusted net income reached $783 million, growing 10% on both a reported and organic operational basis [19][20] - Organic operational revenue growth was balanced, driven by 4% price and 4% volume [19] Business Line Data and Key Metrics Changes - The companion animal portfolio generated $1.8 billion in revenue, growing 8% operationally [20] - The Simparica franchise contributed $448 million, growing 17%, while the key dermatology franchise posted $460 million, growing 11% [20][21] - Livestock revenue declined 2% on an organic operational basis, primarily due to timing of supply [21][27] Market Data and Key Metrics Changes - The U.S. segment grew 4% on a reported basis and 7% on an organic operational basis, with companion animal growing 9% and livestock declining 2% [21][27] - International revenue grew 3% on a reported basis and 9% on an organic operational basis, with companion animal growing 8% and livestock growing 10% [27][31] Company Strategy and Development Direction - The company is focused on innovation and customer engagement, with a strong emphasis on expanding its portfolio and addressing unmet needs in animal health [15][19] - The company raised its full-year guidance for organic operational revenue growth to 6.5% to 8% based on strong first-half performance [17][18] - The strategy includes leveraging first-mover advantages in the parasiticides market and expanding into new therapeutic areas such as renal and oncology [72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the animal health sector, citing strong fundamentals and a diversified portfolio [18][19] - The company is navigating challenges such as tariffs and competitive pressures while maintaining above-market growth [38][39] - Management highlighted the importance of compliance and education in driving adoption of new products like Librela [51][70] Other Important Information - The company reported adjusted gross margins of 73.7%, with a favorable impact from foreign exchange and improved pricing [32] - Adjusted operating expenses increased by 5% operationally, driven by higher advertising and promotion spending [33] Q&A Session Summary Question: Changes in strategy regarding competition in Trioderm franchises - Management noted that they have not changed their strategy and continue to see strong growth in the Simparica franchise despite competition [45][47] Question: Expectations for Librela's growth - Management is focused on medical education and third-party studies to support Librela's adoption, with expectations for growth potentially returning in 2026 [52][70] Question: Strategies to maintain market share in dermatology - Management emphasized the differentiation of their products and the ongoing investment in their pipeline to support growth in the dermatology franchise [77][80] Question: Impact of tariffs on animal health - Management indicated that the tariff environment remains dynamic but expressed confidence in the resilience of the animal health sector [102][104]

Zoetis (ZTS) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.56 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of +8.64%. A quarter ago, it was expected that this animal health company would post earnings of $1.4 per share when it actually produced earnings of $1.48, delivering a surprise of +5.71%. What's Next for Zoetis? While Zoeti ...

Financial Performance - Revenue reached $2.46 billion, a 4% increase compared to the previous year[47] - Adjusted Net Income was $783 million, representing a 10% year-over-year increase[47] - Adjusted Diluted EPS increased to $1.76, a 13% rise compared to the previous year[47] - The company is raising its 2025 revenue outlook to $9450 million - $9600 million[23] - The company is raising its 2025 adjusted net income outlook to $2825 million - $2875 million[23] - The company is raising its 2025 adjusted diluted EPS outlook to $630 - $640[23] Segment Performance - U S segment revenue totaled $1.4 billion, with 7% organic operational growth[20] - U S Companion Animal revenue reached $1.2 billion, a 9% year-over-year increase[20] - International segment revenue amounted to $1.1 billion, showing 9% organic operational growth[20] - International Livestock revenue grew by 10% on an organic operational basis[20] Product Performance - The Simparica franchise experienced 17% operational growth, with revenue reaching $448 million[29] - The Key Dermatology franchise grew by 11% operationally, with revenue reaching $460 million[34] - Livestock revenue increased by 6% on an organic operational basis, reaching $631 million (excluding MFA revenue)[44]

Financial Performance - Zoetis reported revenue of $2.5 billion for Q2 2025, a 4% increase compared to Q2 2024, with an 8% increase on an organic operational basis [3]. - Net income for Q2 2025 was $718 million, or $1.61 per diluted share, reflecting a 15% and 18% increase, respectively, on a reported basis [3]. - Adjusted net income for Q2 2025 was $783 million, or $1.76 per diluted share, marking a 10% and 13% increase on both a reported and organic operational basis [4]. - Revenue for the three months ended June 30, 2025, was $2,460 million, a 4% increase from $2,361 million in 2024 [20]. - Net income attributable to Zoetis Inc. for the three months ended June 30, 2025, was $718 million, up 15% from $624 million in 2024 [20]. - Earnings per share attributable to Zoetis—diluted for the three months ended June 30, 2025, was $1.61, an 18% increase from $1.37 in 2024 [20]. - For the six months ended June 30, 2025, revenue was $4,680 million, a 3% increase from $4,551 million in 2024 [20]. - Net income attributable to Zoetis for the six months ended June 30, 2025, was $1,349 million, a 10% increase from $1,223 million in 2024 [20]. - Earnings per share attributable to Zoetis—diluted for the six months ended June 30, 2025, was $3.02, a 13% increase from $2.67 in 2024 [20]. - The company reported a total earnings increase of 16% to $902 million for the three months ended June 30, 2025 [54]. Revenue Guidance - Zoetis raised its full year 2025 revenue guidance to between $9.450 billion and $9.600 billion, expecting organic operational revenue growth of 6.5% to 8.0% [4]. - Full year 2025 revenue guidance is projected to be between $9,450 million and $9,600 million, with organic operational growth expected between 6.5% and 8.0% [39]. - Adjusted diluted EPS for 2025 is expected to be between $6.30 and $6.40, an increase from the prior guidance of $6.20 to $6.30 [39]. Segment Performance - U.S. segment revenue was $1.4 billion, a 4% increase year-over-year, with a 7% increase on an organic operational basis [5]. - International segment revenue reached $1.1 billion, a 3% increase on a reported basis and a 9% increase on an organic operational basis [5]. - Companion Animal revenue increased by 8% to $1,788 million, while Livestock revenue decreased by 8% to $638 million [44]. - U.S. revenue for the three months was $1,356 million, up 4% from $1,308 million, with a gross margin of 84.7% [54]. - International revenue for the three months was $1,070 million, a 3% increase, with operational revenue growth of 5% [50]. - Livestock revenue in the U.S. decreased by 21% to $180 million, while international livestock revenue decreased by 2% to $458 million [44]. Expenses and Costs - Research and development expenses for the three months ended June 30, 2025, were $172 million, a slight increase of 1% from $171 million in 2024 [20]. - Total costs and expenses for the three months ended June 30, 2025, were $1,558 million, compared to $1,581 million in 2024, reflecting a decrease of 1% [20]. - Selling, general and administrative expenses for the six months ended June 30, 2025, were $1,180 million, a 5% increase from $1,128 million in 2024 [20]. - Adjusted cost of sales for the six months ended June 30, 2025, was $1,267 million, representing a 3% decrease from $1,309 million in 2024 [36]. - Corporate costs rose by 1% to $592 million, while purchase accounting adjustments decreased by 10% to $65 million [61]. - Acquisition and divestiture-related costs decreased by 80% to $1 million, indicating reduced activity in this area [61]. Product Development and Approvals - Zoetis received several new product approvals, including Simparica Trio in Japan and Revolution Plus in Australia, enhancing its product portfolio [7][8]. - The company expects significant product approvals in major markets annually for the next several years, indicating a strong pipeline for future growth [6]. - The company continues to focus on research and development, which is included in other business activities [62]. Operational Efficiency - Significant items for the three months ended June 30, 2025, totaled $47 million pre-tax, compared to $70 million in 2024 [31]. - Certain significant items showed a 30% decrease in costs to $53 million, reflecting improved operational efficiency [61]. - The overall gross profit margin improved from 81.8% to 84.0% in the U.S. segment [61]. - The effective tax rate on adjusted income is expected to be approximately 21% for 2025, consistent with prior guidance [39]. Business Transformation - The company is undergoing a multi-year business process transformation program, which includes the implementation of a new ERP system [34].

Core Viewpoint - Zoetis, Inc. (ZTS) is anticipated to exceed expectations in its second-quarter 2025 earnings report, with projected revenues of $2.4 billion and earnings of $1.61 per share [1][5]. Revenue Sources - The company generates most of its revenue from a diverse portfolio of veterinary medicines and vaccines for livestock and companion animals, with additional income from non-pharmaceutical categories such as nutritional products and precision animal health services [2]. Geographical Performance - Revenues from the United States segment are expected to rise, driven by increased sales of companion animal products, with estimates at $1.33 billion [3]. - The International segment is also projected to see revenue growth, with estimates around $1.05 billion, attributed to higher sales of companion animal products [4]. Product Performance - Strong demand for products like Simparica Trio, Librela, and Apoquel is likely to boost sales in the companion animal segment, while livestock product revenues may decline due to divestitures [5][6]. - Key products contributing to growth include monoclonal antibodies for osteoarthritis pain and flea, tick, and heartworm combination products [6]. Regulatory Approvals - The FDA's recent approval of Simparica Trio for preventing flea tapeworm infections is expected to enhance sales further [8]. Historical Performance - Zoetis has a strong earnings surprise history, surpassing estimates in the last four quarters with an average surprise of 5.21% [12]. Earnings Prediction - The company has an Earnings ESP of +0.42%, indicating a likelihood of beating the consensus estimate of $1.61 per share [14].

Core Viewpoint - Wall Street analysts anticipate Zoetis (ZTS) to report quarterly earnings of $1.61 per share, reflecting a year-over-year increase of 3.2%, with revenues expected to reach $2.4 billion, up 1.7% from the previous year [1] Revenue Estimates - Analysts predict 'Revenues- Contract Manufacturing & Human Health' will reach $21.18 million, indicating a year-over-year change of +17.7% [4] - 'Revenues- Livestock' is expected to be $625.62 million, suggesting a decline of -9.9% year over year [4] - 'Revenues- Companion Animal' is projected to reach $1.76 billion, reflecting a year-over-year increase of +6.7% [4] Product Category Revenue Projections - 'Revenues by major product category- Vaccines' is estimated at $451.72 million, indicating a change of +1.5% from the year-ago quarter [5] - 'Revenues by major product category- Parasiticides' is expected to be $638.60 million, reflecting a change of +6.4% from the previous year [5] - 'Revenues by major product category- Medicated feed additives' is projected at $5.00 million, indicating a significant decline of -93.2% from the prior-year quarter [6] Geographic Revenue Estimates - 'Geographic Revenues- U.S.' is forecasted to reach $1.33 billion, indicating a year-over-year change of +1.7% [6] - 'Geographic Revenues- International Revenue' is expected to be $1.05 billion, reflecting a year-over-year change of +1.3% [6] - 'Geographic Revenues- International- Livestock' is projected at $438.42 million, indicating a decline of -5.9% from the prior-year quarter [7] - 'Geographic Revenues- International- Companion Animal' is expected to reach $618.49 million, reflecting a year-over-year increase of +8.7% [7] - 'Geographic Revenues- U.S.- Livestock' is forecasted to be $202.16 million, indicating a decline of -11.3% from the previous year [8] - 'Geographic Revenues- U.S.- Companion Animal' is projected at $1.15 billion, reflecting a year-over-year change of +6.2% [8] Stock Performance - Zoetis shares have decreased by -6.5% over the past month, contrasting with the Zacks S&P 500 composite's increase of +2.7% [8]

Zoetis (ZTS) ended the recent trading session at $148.81, demonstrating a -1.46% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.13%. On the other hand, the Dow registered a loss of 0.39%, and the technology-centric Nasdaq increased by 0.15%. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual ...